Johnson & Johnson: Success In Multiple Myeloma Underpins $25B In Growth By 2030

Brendan O'Boyle2.84K FollowersFollow5ShareSavePlay(12min)CommentsSummaryJohnson & Johnson earns a Buy rating, driven by the FDA approval of its Tecvayli and Darzalex Faspro combination for R/R multiple myeloma, delivering best-in-class efficacy.This combination therapy achieved an 83.4% 36-month progression-free survival rate, significantly outperforming the control arm and expanding JNJ’s addressable market.JNJ’s oncology pipeline, especially in hematology, is positioned to offset Stelara’s LOE, targeting $50B in oncology sales and $125B total revenue by 2030.With projected 8.6% annual EPS growth and robust margins, JNJ offers a compelling blend of capital appreciation and dividend safety for long-term investors. Sundry Photography/iStock Editorial via Getty Images On March 5th, Johnson & Johnson (JNJ) revealed "unprecedented" Phase 3 data in relapsed/refractory multiple myeloma (RRMM). These data led to the FDA approval of a combination of TecvayliThis article was written byBrendan O'Boyle2.84K FollowersFollowBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.